Literature DB >> 9332562

[Normalization of a computerized visual attention test (TAVIS)].

M Duchesne1, P Mattos.   

Abstract

The authors present the normative data of a computerized test (TAVIS) that address visual attention in children and adolescents being the first neuropsychological instrument as such devised and developed in Brazil. Selective, alternate and sustained attention aspects are evaluated through three different tasks. Omission and action errors as well as time reaction are evaluated. The advantages and limitations of the test are commented.

Entities:  

Mesh:

Year:  1997        PMID: 9332562     DOI: 10.1590/s0004-282x1997000100010

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  The effects of transcranial direct current stimulation on attention and inhibitory control of children and adolescents with attention-deficit/hyperactivity disorder (ADHD): Study protocol for a randomized, sham-controlled, triple-blind, cross-over trial.

Authors:  Rachel Silvany Quadros Guimarães; Igor D Bandeira; Bianca Lima Barretto; Thiago Lima Barretto; Thamires Wanke; Clara Oliveira Carvalho Alves; Chrissie Ferreira de Carvalho; Pedro H Lucena; Luciana Rodrigues-Silva; Rita Lucena
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.889

Review 2.  Interictal Cognitive Performance in Children and Adolescents With Primary Headache: A Narrative Review.

Authors:  Samuela Tarantino; Martina Proietti Checchi; Laura Papetti; Fabiana Ursitti; Giorgia Sforza; Michela Ada Noris Ferilli; Romina Moavero; Gabriele Monte; Teresa Grimaldi Capitello; Federico Vigevano; Massimiliano Valeriani
Journal:  Front Neurol       Date:  2022-07-13       Impact factor: 4.086

3.  Standardization of the normative group for the third version of the test of visual attention - TAVIS.

Authors:  Gabriel Coutinho; Paulo Mattos; Catia Araújo; Manuela Borges; Angela Alfano
Journal:  Dement Neuropsychol       Date:  2008 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.